Dosing convenience

b Compared with other monovalent Hib conjugate vaccines.
c For booster information, please refer to the manufacturer’s Prescribing Information.

PedvaxHIB is administered in a 2-dose primary regimen before 14 months of age—infants 2 to 14 months of age should receive a 0.5 mL dose of vaccine, ideally beginning at 2 months of age, followed by a 0.5 mL dose 2 months later (or as soon as possible thereafter); when the primary 2-dose regimen is completed before 12 months of age, a booster dose (0.5 mL) should be administered at 12 to 15 months, but not earlier than 2 months after the second dose. PedvaxHIB should not be used in infants younger than 6 weeks of age.

A fully liquid formulation

Take advantage—stay with PedvaxHIB. Over 15 years and 28 million doses sold in the United States,³ and we’ve only just begun.

PedvaxHIB is indicated for routine vaccination against invasive disease caused by Haemophilus influenzae type b in infants and children 2 to 71 months of age. PedvaxHIB should not be used in infants younger than 6 weeks of age.

Select safety information

PedvaxHIB is contraindicated in patients with hypersensitivity to any component of the vaccine. Persons who develop symptoms suggestive of hypersensitivity after an injection should not receive further injections of the vaccine.

The most frequently reported (>1%) adverse reactions, without regard to causality, were fever (>101°F), irritability, sleepiness, injection-site pain/soreness, injection-site erythema (<2.5 cm diameter), injection-site swelling/induration (<2.5 cm diameter), unusual high-pitched crying, prolonged crying (>4 hours), diarrhea, vomiting, crying, pain, otitis media, rash, and upper respiratory infection.

Before administering PedvaxHIB, please read the Prescribing Information.

Go to Antibody response or List of benefits.

References: 1. ActHIB [package insert]. Swiftwater, Pa: Sanofi Pasteur, 2000. 2. HibTITER [package insert]. Philadelphia, Pa: Wyeth Pharmaceuticals Inc., 2005. 3. Data available on request from Merck & Co., Inc., Professional Services- DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package 20703489(1)-PED.

PedvaxHIB is a registered trademark of Merck & Co., Inc.